Experimental cell therapy aims to tame dangerous transplant complication
NCT ID NCT06920199
Summary
This early-stage study is testing whether a special type of donor immune cell, called a Treg cell, given along with a protein called interleukin-2, can help control chronic graft-versus-host disease (cGVHD) in patients who haven't responded well to standard steroid treatments. The trial will enroll 18 adults to first find safe dose levels and see how the body handles the treatment. Researchers will also look for early signs that the therapy reduces cGVHD symptoms and allows patients to lower their steroid doses.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CGVHD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai General Hospital
RECRUITINGShanghai, 200080, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.